Profile: Recordati Industria Chimica e Farmaceutica SpA (RECI.MI)
RECI.MI on Milan Stock Exchange
Change (% chg)
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. In October 2013, the Company acquired a 100% stake in Laboratorios Casen Fleet SLU; and approximately 67% of the share capital of Opalia Pharma S.A., a Tunisian pharmaceutical company.
Recordati Industria Chimica e Farmaceutica SpA
Via M. Civitali, 1